secwatch.observer — SEC 8-K summary
======================================

Issuer:     VIVEVE MEDICAL, INC. (—)
CIK:        0000879682
Form:       8-K
Filed at:   2023-01-17T23:59:59+00:00
Accession:  0001437749-23-001076
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.05, 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viveve PURSUIT SUI trial fails primary endpoint; company to delist, reduce workforce, explore sale or wind-down
--------------------------------------------------------------------------------

- PURSUIT trial did not meet primary endpoint: 49.8% active vs 56.7% sham responders (p=0.2035) on 1-hour pad weight test at 12 months.
- Company reducing workforce, exploring strategic alternatives including sale or wind-down of operations.
- Nasdaq will delist stock after Jan 19 hearing; company plans to file Form 15 to suspend SEC reporting.
- No serious device-related adverse events reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879682/000143774923001076/0001437749-23-001076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879682/000143774923001076/vive20230116_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-001076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer